Dr. Uri Geiger
Chairman of the Board
Dr. Geiger is the founder of Exalenz Bioscience, taking the company public in 2007 and serving as its CEO until 2009 and as Chairman since then.
He is also the co-founder and managing partner of Accelmed, a leading medical device investment firm.
Dr. Geiger holds a Doctorate from New York’s Columbia University Center for Law and Economics, where he majored in global equity markets.
Mr. Arkin is one of Israel’s most successful life sciences and pharmaceutical entrepreneurs.
He headed Agis, growing it into a leading dermatological company in the U.S. until its acquisition by Perrigo in 2005 for $818 million. Mr. Arkin has extensive experience in the development and commercialization of pharmaceutical drug products, having held leadership roles in several companies with significant ties to innovative and generic drug companies.
He holds a degree in psychology and philosophy from the Tel Aviv University.
After completing his internship at Sphera investment fund, Mr. Arkin joined Arkin Holdings in March 2014, as a research analyst for market research in the field of dermatology and investments. He serves on the board of directors of Exalenz Bioscience, and is also a member of both Accelmed and Sphera Global Healthcare investment committees.
Mr. Arkin graduated with honors a BA degree in Business Administration from IDC Herzliya.
Mrs. Lerman, who joined Arkin Holdings as CFO in 2015, has been a finance executive and consultant for more than 15 years. She serves as a board member of several companies, including Sphera Global Healthcare, Exalenz Bioscience, and Medical Compression Systems. Prior to joining Arkin Holdings, she was CFO of high-tech companies including, Discretix, Storwize and SunGard Business Integration.
She holds an MBA, with a major in Finance from Tel Aviv University, a B.A. in Economics and Accounting.
Mr. Avi Zigelman is on the Board of Directors at Ormat Industries Ltd., Mizrahi Tefahot Bank Ltd., Sialo Technology Ltd., Gindi Investments 1 Ltd., Plastro Irrigation Systems Ltd., Migdal Capital Markets (1965) Ltd. and Ultra Equity Investments Ltd.
He was previously employed as Independent External Director by Clal Biotechnology Industries Ltd. and an Independent Director by Crow Technologies 1977 Ltd.
He also served on the board at D.G.C. Group Ltd., Tefron Ltd., Israel Canada (T.R) Ltd.
He holds an M.A. Degree in Business Economics, specialization in Finance, with honors, B.A in Accounting and Economics, Economics with honors and Post Degree Accounting Studies, with honors, all from Tel-Aviv University.
Prof. Gadi Keren
Mr. Keren, MD, has been Professor of Cardiology at Tel-Aviv University’s Sackler School of Medicine since 1994. Prof. Keren serves as Head of the Department of Cardiology at the Tel Aviv Medical Center. He served as Medical Director of B-Balloon Ltd.
in addition to several other innovative medical device companies. Prof. Keren has held the Chaim Sheba Chair of Cardiology at Tel Aviv University since 2005 and was a research fellow at the National Institute of Health in 1989 and 1990. He has co-authored over 200 original articles, numerous case reports and review article and written numerous patents in the field of cardiovascular therapeutics.
Prof. Keren is board certified in Cardiology-Israel and holds a M.D in Medicine from Tel-Aviv University and a B.A in Philosophy from Tel-Aviv University
Mr. Kochan serves as International President and Branded Consumer Healthcare for Perrigo Company, a leading global healthcare supplier that develops, manufactures and distributes Over-The-Counter (OTC), Prescription (Rx) pharmaceuticals, Nutritional products, Animal Health, Diagnostics and API’s, with annual sales exceeding $5B. Sharon started his career in healthcare with Clay-Park Labs, NY, in 1994 as a project manager, and grew through the ranks, and by way of acquisition to join Perrigo executive committee in 2007 and assume various senior leadership, operational and strategic roles with Perrigo.
Mr. Sharon holds a BSc. degree in Industrial Engineering, cum laude, from Tel-Aviv University (1994), and MSc. degree in Operations Research – Management Science, with scholarship, from Columbia University, in NYC (1996).
Shmuel (Milky) Rubinstein
For the last few years Mr. Rubinstein serves as a board member in the following companies: Clal Bio Technologies, Exalenz BioSicence ,Medison Biotech, Trima Phrma, Tiltan Pharma (Chairman of the Board) and as a consultant to BDO and Sol-Gel Pharma.
Milky acted as the CEO and General Manager of Taro Pharmaceuticals Industries Ltd. Over 20 years. During those years, Taro became a public company and was traded in the Israel Stock Exchange and since 1994 on NASDAQ. Under his management, Taro grew to become a multinational company with over 1000 employees worldwide and turnover of close to 450 Miliion dollars.
On 2003, Milky received the Exceptional Industrialist Reward.